1. Home
  2. VRAX

as of 08-18-2026 4:00pm EST

$2.76
$0.05
-1.78%
Stocks Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances Nasdaq

Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.

Founded: 2013 Country:
United Kingdom
United Kingdom
Employees: N/A City: N/A
Market Cap: 2.3M IPO Year: 2021
Target Price: $1.00 AVG Volume (30 days): 65.5K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $0.10 - $13.19 Next Earning Date: 06-12-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 217274.83% Revenue Growth (next year): -70.35%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered VRAX Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 21 hours ago

AI Recommendation

hold
Model Accuracy: 70.56%
70.56%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: